OptiMalVax: Optimizing A Deployable High Efficacy Malaria Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$494,618.00
Summary
In this proposal, a consortium comprising many of the leading malariologists, vaccine researchers and product developers in Europe, USA, Australia and Africa will collaborate in an exciting programme of antigen discovery science linked to rapid clinical development of new vaccine candidates against malaria.
Development Of A Safe Live Genetically Attenuated Blood Stage Malaria Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$822,191.00
Summary
Malaria presents an enormous global health problem, and also has a significant impact on social and economic development in countries where the disease is endemic. Our project will produce a live genetically-modified vaccine against Plasmodium falciparum, the parasite that causes the form of malaria mostly deadly to humans. Our development plan will include the first ever clinical trials of a malaria vaccine of this kind and will look at vaccine safety and effectiveness.
Formulation Of A Pan-species, Multi-stage Vaccine For The Malaria Eradication Agenda
Funder
National Health and Medical Research Council
Funding Amount
$777,611.00
Summary
GNT 1093311 entitled 'Formulation of a pan-species, multi-stage vaccine for the malaria eradication agenda' seeks to undertake the preclinical development of a saccharide conjugate vaccine directed towards all major species and stages of malaria. The objectives are: (i) to undertake the synthesis of the vaccine construct; (ii) to compare immunogenicity, formulation and efficacy of various vaccine constructs with a view to down-selecting the optimal combination to take to human clinical trial.
Immunological Control Of Cysticercosis And Hydatid Disease
Funder
National Health and Medical Research Council
Funding Amount
$828,300.00
Summary
In this project the world’s most effective vaccines against diseases caused by parasites will be translated from the laboratory to the clinic. The vaccines prevent transmission of parasites from livestock animals to humans. During the next 5 years the vaccines will be produced on a large scale and evaluated in field trials. The products of this research program will make a major contribution to reducing the number of people suffering from parasitic cysts.
We will investigate malaria, a parasitic disease that kills over 600,000 people a year. We will explore how the parasite identifies, invades and remodels the host cells in which it lives, scavenging nutrients and hiding from the immune system. We will characterize the proteins involved in these critical events, as they are potential targets for drugs and vaccines. We will study how parasites cause disease and how the host responds to infection.
A Transmission-Blocking Vaccine To Prevent Toxoplasmosis
Funder
National Health and Medical Research Council
Funding Amount
$850,225.00
Summary
Toxoplasma gondii causes a globally important zoonotic disease. It is transmitted by cats, and finds its way into our food chain via infected meat and contaminated water. We have used a unique functional genomics pipeline to discover proteins crucial for reproduction of Toxoplasma in the cat. We will now test combinations of these proteins to immunise cats and prove that we can develop a vaccine that blocks transmission of this highly significant parasitic disease.
Helminth Secretomes: From Vaccines To Novel Anti-inflammatory Biologics
Funder
National Health and Medical Research Council
Funding Amount
$938,910.00
Summary
Billions of people in developing countries are infected with parasitic worms, but they have been eradicated from industrialised nations. Humans co-evolved with worms, so their recent removal has deprived us of signals required to keep inflammation in check. My research focuses on worm molecules that can be used to (1) develop vaccines to combat these parasitic infections in developing countries, and (2) as a novel platform of anti-inflammatory therapeutics for use in industrialised nations.
Helminth Secreted Proteins – From Anthelmintic Vaccines To Therapies For Autoimmunity
Funder
National Health and Medical Research Council
Funding Amount
$739,893.00
Summary
Human helminths (worms) cause chronic disease in developing countries, yet their disappearance from developed countries has been accompanied by an increase in the prevalence of autoimmune and allergic diseases. My resesarch focuses on the proteins these worms secrete and their use in (1) the development of anthelmintic vaccines, and (2) the development of novel anti-inflammatory molecules to treat autoimmunity, particularly diseases affecting the gut.
Immunological Prevention Of Cysticercosis And Hydatid Disease
Funder
National Health and Medical Research Council
Funding Amount
$510,000.00
Summary
Cysticercosis and hydatid disease are caused by infections with the larval stages of tapeworm parasites. These infections cause substantial morbidity and mortality throughout the world, but particularly in developing countries. They are zoonotic diseases, being transmitted to humans from animals. This project aims to develop practical vaccines to assist with the prevention of both cysticercosis and hydatid disease in humans. The vaccines will be used in the parasites' natural animal hosts, there ....Cysticercosis and hydatid disease are caused by infections with the larval stages of tapeworm parasites. These infections cause substantial morbidity and mortality throughout the world, but particularly in developing countries. They are zoonotic diseases, being transmitted to humans from animals. This project aims to develop practical vaccines to assist with the prevention of both cysticercosis and hydatid disease in humans. The vaccines will be used in the parasites' natural animal hosts, thereby breaking the parasite life-cycle and preventing the diseases being passed to humans. Substantial preliminary research has been undertaken by the applicant, including completion of successful preliminary vaccine trials. This project will optimise the vaccines and complete initial field trials in countries with high rates of disease transmission.Read moreRead less